iRhythm Holdings, Inc.

IRTC

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001388658

A

strongest fifth of 305 graded peers in healthcare

rank 20 of 305; percentile 6.2; sampling error 2.8 points; lower is stronger

A B C D E


A, the bull



Scoreboard


Profitability	B	percentile 26.8
Solvency	B/C	percentile 38.0
Growth and financing	B	percentile 26.9
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $1.0B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet	
Inputs computable	8 of 13	
Graded from	filings received through Feb 19, 2026	273 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$94.89	2026-11-18; market equity $3.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 26.8						
Gross profitability	51.7%	32.8%		22.0	346	2025-12-31
Return on invested capital	not computable	9.6%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(12.9%)	(6.7%)		33.4	756	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.5 pts	2.8 pts	25.0	237	2025-12-31
Solvency, sleeve percentile 38.0					
Altman Z double-prime	0.78	0.31	35.2	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	4.63x	2.68x	40.8	781	2025-12-31
Growth and financing, sleeve percentile 26.9					
Revenue growth, three-year compound	22.1%	9.6%	29.3	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	31.5%	3.2%	14.5	663	2025-12-31
Net share issuance, one year	2.9%	1.6%	37.0	625	2026-02-12


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 117,872,000 USD; Altman Z is not used

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
15	Biomarin Pharmaceutical Inc. (BMRN)	4.6	A	
16	Exelixis, Inc. (EXEL)	4.9	A	fortress balance sheet
17	Corcept Therapeutics Inc. (CORT)	5.3	A	fortress balance sheet
18	Neurocrine Biosciences Inc. (NBIX)	5.6	A	
19	AtriCure, Inc. (ATRC)	5.9	A	
20	iRhythm Holdings, Inc. (IRTC)	6.2	A	fortress balance sheet
21	Intuitive Surgical Inc. (ISRG)	6.6	A	
22	Gyre Therapeutics, Inc. (GYRE)	6.9	A	fortress balance sheet
23	Vericel Corp. (VCEL)	7.2	A	
24	United Therapeutics Corp. (UTHR)	7.6	A	
25	Hims & Hers Health, Inc. (HIMS)	7.9	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-18 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(39.3%)	(1.7%)	23
Distance from 52-week high	(49.9%)	(30.2%)	32
EBIT to enterprise value	(2.0%)	0.5%	42
Free cash flow yield	1.1%	0.6%	54
Book value to price	0.06	0.29	17
Sales to price	0.23	0.36	36
Composite equity issuance, five years	14.2%	13.5%	51
Relative strength against the sector, log excess return	(0.67)	(0.19)	23
Twelve-month failure probability, CHS model	0.08%	0.06%	57

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$394.7M
Operating cash flow, four quarters	$55.6M
Months of runway	not finite
Days since last periodic filing	14 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$55.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$527.2M	2025-12-31	2026-02-19	10-K	26-000011
2	assets	us-gaap:Assets	$1.0B	2025-12-31	2026-02-19	10-K	26-000011
3	operating income	us-gaap:OperatingIncomeLoss	-$99.9M	2021-12-31	2024-02-22	10-K	24-000014
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$101.0M	2021-12-31	2024-02-22	10-K	24-000014
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$367,000	2021-12-31	2024-02-22	10-K	24-000014
6	total debt	us-gaap:LongTermDebt	$9.7M	2021-12-31	2022-02-28	10-K	22-000020
7	book equity	us-gaap:StockholdersEquity	$279.5M	2021-12-31	2025-02-20	10-K	25-000028
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$127.6M	2021-12-31	2023-02-23	10-K	23-000007
9	total debt	us-gaap:LongTermDebt	$21.3M	2020-12-31	2022-02-28	10-K	22-000020
10	book equity	us-gaap:StockholdersEquity	$341.6M	2020-12-31	2024-02-22	10-K	24-000014
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$88.6M	2020-12-31	2022-02-28	10-K	22-000020
12	net income	us-gaap:NetIncomeLoss	-$44.6M	2025-12-31	2026-02-19	10-K	26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$80.9M	2025-12-31	2026-02-19	10-K	26-000011
14	assets	us-gaap:Assets	$931.4M	2024-12-31	2026-02-19	10-K	26-000011
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$747.1M	2025-12-31	2026-02-19	10-K	26-000011
16	gross profit	us-gaap:GrossProfit	$407.5M	2024-12-31	2026-02-19	10-K	26-000011
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$591.8M	2024-12-31	2026-02-19	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	gross profit	us-gaap:GrossProfit	$331.8M	2023-12-31	2026-02-19	10-K	26-000011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$492.7M	2023-12-31	2026-02-19	10-K	26-000011
20	gross profit	us-gaap:GrossProfit	$281.6M	2022-12-31	2025-02-20	10-K	25-000028
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$410.9M	2022-12-31	2025-02-20	10-K	25-000028
22	gross profit	us-gaap:GrossProfit	$213.6M	2021-12-31	2024-02-22	10-K	24-000014
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$322.8M	2021-12-31	2024-02-22	10-K	24-000014
24	current assets	us-gaap:AssetsCurrent	$702.8M	2025-12-31	2026-02-19	10-K	26-000011
25	current liabilities	us-gaap:LiabilitiesCurrent	$151.9M	2025-12-31	2026-02-19	10-K	26-000011
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$803.4M	2025-12-31	2026-02-19	10-K	26-000011
27	operating income	us-gaap:OperatingIncomeLoss	-$57.4M	2025-12-31	2026-02-19	10-K	26-000011
28	book equity	us-gaap:StockholdersEquity	$152.7M	2025-12-31	2026-02-19	10-K	26-000011
29	liabilities	us-gaap:Liabilities	$867.3M	2025-12-31	2026-02-19	10-K	26-000011
30	operating income	us-gaap:OperatingIncomeLoss	-$125.2M	2023-12-31	2026-02-19	10-K	26-000011
31	interest expense	us-gaap:InterestExpense	$3.6M	2023-12-31	2024-02-22	10-K	24-000014
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$46.3M	2025-12-31	2026-02-19	10-K	26-000011
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.4M	2024-12-31	2026-02-19	10-K	26-000011
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33.9M	2024-12-31	2026-02-19	10-K	26-000011
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$50.1M	2023-12-31	2026-02-19	10-K	26-000011
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$40.4M	2023-12-31	2026-02-19	10-K	26-000011
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$23.0M	2022-12-31	2025-02-20	10-K	25-000028
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$29.8M	2022-12-31	2025-02-20	10-K	25-000028
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$20.7M	2025-12-31	2026-02-19	10-K	26-000011
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$43.6M	2025-12-31	2026-02-19	10-K	26-000011
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$953,000	2025-12-31	2026-02-19	10-K	26-000011
42	current assets	us-gaap:AssetsCurrent	$645.8M	2024-12-31	2026-02-19	10-K	26-000011
43	current liabilities	us-gaap:LiabilitiesCurrent	$110.9M	2024-12-31	2026-02-19	10-K	26-000011
44	assets	us-gaap:Assets	$433.1M	2023-12-31	2025-02-20	10-K	25-000028
45	assets	us-gaap:Assets	$448.2M	2022-12-31	2024-02-22	10-K	24-000014
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,316,760	2026-02-12	2026-02-19	10-K	26-000011
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,409,617	2025-02-13	2025-02-20	10-K	25-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.